Moshe Ben-Shoshan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Moshe Ben-Shoshan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Lawrence Joseph
Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center
3 shared publicationsMarie-Noël Primeau
Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics
3 shared publicationsAnn Clarke
Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center
2 shared publicationsClaire Dufresne
Association Québécoise des Allergies Alimentaires (AQAA), Montreal, Quebec, Canada
2 shared publicationsElizabeth Turnbull
Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center
2 shared publicationsReza Alizadehfar
Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics
2 shared publications
Latest Publications
Anaphylaxis: past, present and future
Anaphylaxis is a clinical emergency, and recent reports suggest increased prevalence. A diverse set of primary genetic and environmental influences may confer susceptibility to anaphylactic reactions. Anaphylaxis presents diagnostic and therapeutic challenges. It often manifests with a broad array of symptoms and signs that might be similar to other diseases. The management of anaphylaxis consists of emergency treatment of acute episodes as well as preventive strategies to avoid recurrences. Treatment is complicated by its rapid onset and progression, presence of concurrent diseases or medications, and need for long-term allergen avoidance. Health care professionals must be able to recognize the signs of anaphylaxis, treat an episode promptly and appropriately, and provide preventive recommendations. Recognizing the gaps in our understanding and management of anaphylaxis may help identify promising targets for future treatment and prevention and areas that require further study.
Anaphylaxis: past, present and future
Anaphylaxis is a clinical emergency, and recent reports suggest increased prevalence. A diverse set of primary genetic and environmental influences may confer susceptibility to anaphylactic reactions. Anaphylaxis presents diagnostic and therapeutic challenges. It often manifests with a broad array of symptoms and signs that might be similar to other diseases. The management of anaphylaxis consists of emergency treatment of acute episodes as well as preventive strategies to avoid recurrences. Treatment is complicated by its rapid onset and progression, presence of concurrent diseases or medications, and need for long-term allergen avoidance. Health care professionals must be able to recognize the signs of anaphylaxis, treat an episode promptly and appropriately, and provide preventive recommendations. Recognizing the gaps in our understanding and management of anaphylaxis may help identify promising targets for future treatment and prevention and areas that require further study.
- 1 November 2010
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 4 (3) , 183-92
Omalizumab for asthma: indications, off-label uses and future directions.
Abstract: Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However, recent reports and patents suggest wider applications in asthma and related diseases. In this review unmet needs and future directions regarding the use of omalizumab in asthma are discussed. Better understanding of omalizumabs mechanisms of action on one hand and asthma and related pathogenesis on the other hand might contribute to the development of better future guidelines of omalizumab use in asthma patients.
- 1 November 2010
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 4 (3) , 183-92
Omalizumab for asthma: indications, off-label uses and future directions.
Abstract: Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However, recent reports and patents suggest wider applications in asthma and related diseases. In this review unmet needs and future directions regarding the use of omalizumab in asthma are discussed. Better understanding of omalizumabs mechanisms of action on one hand and asthma and related pathogenesis on the other hand might contribute to the development of better future guidelines of omalizumab use in asthma patients.
- 18 August 2010
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 21 (6) , 920-926
Establishing the diagnosis of peanut allergy in children never exposed to peanut or with an uncertain history: a cross-Canada study
- 18 August 2010
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 21 (6) , 920-926
Establishing the diagnosis of peanut allergy in children never exposed to peanut or with an uncertain history: a cross-Canada study
- Open Access
- 1 June 2010
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 125 (6) , 1327-1335
A population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada
- 1 June 2010
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 125 (6) , 1327-1335
Open AccessA population-based study on peanut, tree nut, fish, shellfish, and sesame allergy prevalence in Canada
- 1 July 2009
- Published by Wiley in Pediatric Dermatology
- Vol. 26 (4) , 481-482
The Predilection of Chickenpox Exanthema to Influenza Vaccine Injection Site
Annual influenza immunization of children is highly recommended and is usually well tolerated. We report the first case of chickenpox exanthema localized to the influenza vaccination site in a boy with known egg allergy.
- 1 July 2009
- Published by Wiley in Pediatric Dermatology
- Vol. 26 (4) , 481-482
The Predilection of Chickenpox Exanthema to Influenza Vaccine Injection Site
Annual influenza immunization of children is highly recommended and is usually well tolerated. We report the first case of chickenpox exanthema localized to the influenza vaccination site in a boy with known egg allergy.
- 1 June 2009
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 3 (2) , 132-142
CTLA-4Ig: Uses and Future Directions
Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a member of the CD28 receptor family. Blocking CD28 interaction with its ligands through the use of CTLA-4Ig might contribute to better control of dysregulated immune response processes. The ligands binding to CTLA-4 are the B7 family members, B7-1 (CD80) and B7-2 (CD86). CTLA-4Ig is now a Food and Drug Administration-approved drug for use treating patients with Rheumatoid arthritis (RA) but its use is explored also in other autoimmune diseases, transplantation as well as allergic diseases. Patents related to CTLA-4 function as well as possible clinical applications are discussed in this paper.
- 1 June 2009
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 3 (2) , 132-142
CTLA-4Ig: Uses and Future Directions
Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a member of the CD28 receptor family. Blocking CD28 interaction with its ligands through the use of CTLA-4Ig might contribute to better control of dysregulated immune response processes. The ligands binding to CTLA-4 are the B7 family members, B7-1 (CD80) and B7-2 (CD86). CTLA-4Ig is now a Food and Drug Administration-approved drug for use treating patients with Rheumatoid arthritis (RA) but its use is explored also in other autoimmune diseases, transplantation as well as allergic diseases. Patents related to CTLA-4 function as well as possible clinical applications are discussed in this paper.
- 1 November 2008
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 2 (3) , 191-201
Omalizumab: Not Only For Asthma
Abstract: Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However, recent studies suggest that omalizumab might play an important role in the treatment of other potentially IgE mediated disease processes including: urticaria and angioedema, atopic dermatitis, allergic rhinitis, nasal polyposis and severe ocular allergies. Furthermore, addition of omalizumab to immunotherapy protocols is reported to be highly advantageous. Although omalizumab is generally well tolerated, reports on potential anaphylactic reactions as well as an association with Churg-Strauss syndrome necessitate close monitoring. The data reviewed are discussed with the aim of underlining unmet needs and making recommendations for future studies on omalizumab use. This might better guide future clinical practice regarding omalizumab treatment. This review article also discussed some patent related to the field.
- 1 November 2008
- Published by Bentham Science Publishers Ltd. in Recent Patents on Inflammation & Allergy Drug Discovery
- Vol. 2 (3) , 191-201
Omalizumab: Not Only For Asthma
Abstract: Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However, recent studies suggest that omalizumab might play an important role in the treatment of other potentially IgE mediated disease processes including: urticaria and angioedema, atopic dermatitis, allergic rhinitis, nasal polyposis and severe ocular allergies. Furthermore, addition of omalizumab to immunotherapy protocols is reported to be highly advantageous. Although omalizumab is generally well tolerated, reports on potential anaphylactic reactions as well as an association with Churg-Strauss syndrome necessitate close monitoring. The data reviewed are discussed with the aim of underlining unmet needs and making recommendations for future studies on omalizumab use. This might better guide future clinical practice regarding omalizumab treatment. This review article also discussed some patent related to the field.
- 1 June 2008
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 100 (6) , 570-575
Availability of the epinephrine autoinjector at school in children with peanut allergy
- 1 June 2008
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 100 (6) , 570-575
Availability of the epinephrine autoinjector at school in children with peanut allergy